Cutia Therapeutics Company Description

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.

It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication.

The company’s products include CU-40102, a topical finasteride spray approved for androgenetic alopecia treatment; CU-10201, a topical 4% minocycline foam, for acne vulgaris treatment; and CU-10101, a topical novel small molecule agent, and a non-hormonal and small molecule drug, which is in Phase I, for the treatment of mild to moderate atopic dermatitis.

It is also involved in the development of CU-20401, a recombinant mutant collagenase, currently under Phase II clinical trial for submental adipose accumulation (submental fat); CU-40101, a topical small molecule thyroid hormone receptor agonist liniment, currently completed Phase I clinical trial for the treatment of androgenetic alopecia; and CU-30101, a localized topical lidocaine and tetracaine compound topical anesthesia cream, completed Phase III clinical trial for surface dermatologic operations.

In addition, the company provides CATAME, a technology platform that enables the development of a wide range of product dosage forms and the relevant formulation technology.

Further, it offers product pipeline of creams, sprays, ointments, aerosol foams and other dosage forms through the CATAME platform.

The company was incorporated in 2019 and is headquartered in Shanghai, China.